Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
September 26, 2023 08:00 ET
|
Vaccinex, Inc.
"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer’s Disease...
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
June 21, 2023 07:05 ET
|
uniQure Inc.
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural...
Rumi Scientific Announces Data Demonstrating Disease Modifying Effect of BRD9 Inhibition in a Huntington’s Disease Animal Model
April 26, 2023 07:05 ET
|
Rumi Scientific, Inc.
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (“Rumi”), a developer of therapies for rare and neurodegenerative diseases discovered using its high throughput organoid phenotypic...
Rumi Scientific Appoints Allen A. Fienberg, Ph.D., as Chief Executive Officer and Chairman of the Board of Directors
March 30, 2023 08:00 ET
|
Rumi Scientific, Inc.
NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (“Rumi”), a developer of therapies for rare and neurodegenerative diseases discovered using its high throughput organoid phenotypic...
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 22, 2023 07:30 ET
|
Wave Life Sciences USA, Inc.
Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic Extended...
Hereditary Disease Foundation Announces 2022 Prize Winners for Leadership in Huntington’s Disease Research
October 19, 2022 11:02 ET
|
Hereditary Disease Foundation
New York, Oct. 19, 2022 (GLOBE NEWSWIRE) -- The Hereditary Disease Foundation today announced the winners of its 2022 prizes for leadership in Huntington’s disease research. -- Steven...
Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease
September 20, 2022 07:30 ET
|
Wave Life Sciences USA, Inc.
Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 or 60 mg; mean mHTT reduction across both cohorts...
Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation
August 08, 2022 11:00 ET
|
Vaccinex, Inc.
Data suggest that pepinemab slows or prevents cognitive decline in Huntington’s Disease (HD) Results highlight the potential for impact on other neurodegenerative and neuroinflammatory diseases...
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
June 23, 2022 07:05 ET
|
uniQure Inc.
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed...
Neurodegenerative Diseases Market to reach USD 53 Billion by 2030 and grow steadily at a CAGR of 3.2%: Straits Research
May 27, 2022 11:30 ET
|
Straits Research
New York, United States, May 27, 2022 (GLOBE NEWSWIRE) -- Neurodegenerative diseases are a large and diverse group of disorders characterized by progressive deterioration of the function and...